Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform do ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics , a leader in the ...

For information, the company have announced that the STIMULUS program for Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes has been terminated and therefore they will no ...